Список литературы (факмакокинетика и фармакодинамика)

Статьи
Предупреждение! Препарат рецептурного отпуска! Использовать только после назначения врача!
Xefocam® Монография
  1. Atzpodien E, Mehdi N, Clarke D, Radhofer-Welte S. Subacute and chronic oral toxicity of lornoxicam in cynomolgus monkeys. Food Chem. Toxicol. 35[5], 465-474. 1997.
  2. El Dareer SM, Noker PE, Galbraith WM. Disposition of [14C] lornoxicam in male and female cynomolgus monkeys dosed orally or intravenously. The FASEB Journal 4[3], A461 (Abstr. 1132). 1990.
  3. Fukuzaki K, Koja T, Kamenosono T, Nagatomo M, Nagata R, Tanaka M et al. General pharmacological studies of Lornoxicam. Japanese Pharmacology and Therapeutics 25[2], 81-101. 1997.
  4. Jolliet P, Bree F, Urien S, Albengres E, Tillement JP. Blood to brain transfer of various oxicams: Comparison of the effects of plasma binding on their delivery to the brain. Conference de Biologie Cerebro-Vasculaire [Abstract]. 1995.
  5. Pohlmeyer-Esch G, Mehdi N, Clarke D, Radhofer-Welte S. Evaluation of chronic oral toxicity and carcinogenic potential of lornoxicam in rats. Food Chem. Toxicol. 35[9], 909-922. 1997.
  6. Pruss TP, Stroissnig H, Radhofer-Welte S, Wendtlandt W, Mehdi N, Takacs F et al. Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam. Postgraduate Medical Journal 66 [Suppl. 4], S18-S21. 1990.
  7. Urano H, Shinohara K, Yamaguchi J, Itomasa H, Suwa T. Metabolic fate of TS-110, a new anti-inflammatory agent (1). Metabolism in rats. 112th Annual Meeting of the Pharmaceutical Society of Japan, Fukuoka, Abstract 31 KA 10-82. 1992.
  8. Pruss TP, Stroissnig H, Ferber HP. Lornoxicam, a novel highly potent anti-inflammatory and analgesic agent which does not penetrate the brain. 3rd Interscience world conference on inflammation, antirheumatics, analgesics, immunomodulators, Monte Carlo , 41. 1989.
  9. McCormack K. The spinal actions of nonsteroidal anti-inflammatory drugs and the dissociation between their anti-inflammatory and analgesic effects. Drugs 47 Suppl 5, 28-45. 1994.
  10. Berg J, Christoph T, Bodenteich A. Isoenzyme-specific cyclooxygenase inhibitors: a whole cell assay system using the human erythroleukemic cell line HEL and the human monocytic cell line Mono Mac 6. Journal of Pharmacological and Toxicological Methods 37[4], 179-186. 1997.
  11. Futaki N, Takahashi S, Kitagawa T, Yamakawa Y, Tanaka M, Higuchi S. Anti-inflammatory, analgesic, antipyretic and cyclooxygenase inhibitory effects of a non-steroidal anti-inflammatory agent, Lornoxicam. Japanese Pharmacology and Therapeutics 25[4], 55-71. 1997.
  12. Balfour JA, Fitton A, Barradell LB. Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs 51[4], 639-657. 1996.
  13. Kullich W, Klein G. Influence of the nonsteroidal antiinflammatory drug lornoxicam i.v. on the secretion of the endogenous opiate peptides dynorphin and beta-endorphin. Aktuelle Rheumatologie 17, No.4, 128-132. 1992.
  14. Stimmeder D. Antinociceptive effects of lornoxicam in the PBQ writhing test in mice, iv vs icv administration. Data on File, editor. 1992. Nycomed.
  15. Buritova J, Besson JM. Dose-related anti-inflammatory/analgesic effects of lornoxicam: a spinal c-Fos protein study in the rat. Inflamm. Res. 47[1], 18-25. 1998.
  16. Bianchi M, Panerai AE. Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hindpaw hyperalgesia induced by formalin injection in rat tail. Pharmacol. Res. 45[2], 101-105. 2002.
  17. Abramson SB, Weissmann G. The mechanisms of action of non-steroidal anti-inflammatory drugs. Arthritis Rheum. 32[1], 1-9. 1989.
  18. Cashin CH, Meen ND. Antipyretic activity of anti-inflammatory drugs in rats: results of testing indomethacin, carprofen, diclofenac, piroxicam and Paracetamol in comparison with Ro 13-9297, Ro 14-0046 and Ro 14-1419. Roche Internal Research Report No. 178. Data on File, editor. 1980. Nycomed.
  19. Dittrich P. Bioavailability of Lornoxicam after 8 mg i. v., 8 mg i. m., 8 mg as suppository, 8 mg p. o., 16 mg p. o. (CT 64). Data on File, editor. 18-5-1993. Nycomed.
  20. Skjodt NM, Davies NM. Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. Clin. Pharmacokinet. 34[6], 421-428. 1998.
  21. Nahler G. The pharmacokinetics of C-14-Chlortenoxicam (= Lornoxicam) applied as oral solution (CT 38 and CT 38A). Data on File, editor. 28-4-1993. Nycomed.
  22. Hitzenberger G, Radhofer-Welte S, Takacs F, Rosenow D. Pharmacokinetics of lornoxicam in man. Postgraduate Medical Journal 66, Suppl. 4, S22-S26. 1990.
  23. Ankier SI, Brimelow AE, Crome P, Johnston A, Warrington SJ, Turner P et al. Chlortenoxicam pharmacokinetics in young and elderly human volunteers. Postgraduate Medical Journal 64, 752-754. 1988.
  24. Strobel W. Phase I, Single Centre Study to Evaluate the Pharmacokinetics of Lornoxicam in 24 (12 Elderly and 12 Young) Healthy Volunteers After Single and Multiple Dose Conditions (CT 81). Data on File, editor. 28-4-1995. Nycomed.
  25. Mayerhofer S, Welte S, Magometschnigg D, Ferber HP. The effect of food on pharmacokinetic parameters of the new НПВП lornoxicam in healthy volunteers. 3rd Interscience world conference on inflammation, antirheumatics, analgesics, immunmodulators, Monte Carlo , 223. 1989.
  26. Dittrich P, Radhofer-Welte S, Mayerhofer S, Kukovetz WR, Ferber HP. Comparative pharmacokinetics of parenteral lornoxicam. Eur. J. Pharmacol. 183, 2265-2266. 1990.
  27. Dittrich P, Radhofer-Welte S, Magometschnigg D, Kukovetz WR, Mayerhofer S, Ferber HP. The effect of concomitantly administered antacids on the bioavailability of lornoxicam, a novel highly potent НПВП. Drugs Exp. Clin. Res. 16 (2), 57-62. 1990.
  28. Radhofer-Welte S, Danneskiold-Samsoe P, Grarup J. The pharmacokinetics of lornoxicam as quick release tablet, standard tablet and intramuscular injection. Not Available. 2003.
  29. Geisler J. Study for Evaluation of the Pharmacokinetics after Multiple Dose Administration of Lornoxicam 8 mg Tablets in Patients with Impaired Liver Function Compared to Healthy Controls (CT 73). Data on File, editor. 21-7-1993. Nycomed.
  30. Albengres E, Urien S, Barre J, Nguyen P, Bree F, Jolliet P et al. Clinical pharmacology of oxicams: New insights into the mechanisms of their dose-dependent toxicity. International Journal of Tissue Reaction 15[3], 125-134. 1993.
  31. Olkkola KT, Brunetto AV, Mattila MJ. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin. Pharmacokinetics 26[2], 107-120. 1994.
  32. Radhofer-Welte S, Dittrich P. Determination of the novel non-steroidal anti-inflammatory drug lornoxicam and its main metabolite in plasma and synovial fluid. J. Chromatogr. B Biomed. Sci. Appl. 707[1-2], 151-159. 10-4-1998.
  33. Kohl Ch, Kocian M, Paschinger D, Radhofer S. Interactions of potent tolbutamide 4-hydroxylase inhibitors with the metabolism of Lornoxicam in human liver microsomes. ISSX Procceedings 11, 166. 1997.
  34. Unseld E, Radhofer-Welte S, Molz K-H, Haug-Pihale G, Grune D, Frenzel W. Disposition of lornoxicam and its 5'-hydroxy-metabolite in relation to the sparteine and mephenytoin oxidation polymorphism. European Journal of Drug Metabolism and Pharmacokinetics- Proc. Europ. Congr. Biopharm. Pharmacok.,Brussels, 87-93. 1994.
  35. Bonnabry P, Dayer P, Leemann T. Role of human liver cytochrome P450TB (CYP2C9) in the biotransformation of Lornoxicam. Clin. Pharmacology and Therapeutics 57[2 - Abstract PI-70], 152. 1995.
  36. Bonnabry P, Leemann T, Dayer P. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur. J. Clin. Pharmacol. 49[4], 305-308. 1996.
  37. Kohl C, Steinkellner M. Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. Drug Metab Dispos. 28[2], 161-168. 2000.
  38. Iida I, Miyata A, Arai M, Hirota M, Akimoto M, Higuchi S et al. Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5'-hydroxylation. Drug Metab Dispos. 32[1], 7-9. 2004.
  39. Zhang Y, Zhong D, Si D, Guo Y, Chen X, Zhou H. Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. Br. J. Clin. Pharmacol. 59[1], 14-17. 2005.
  40. Anthony M, Berg MJ. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part I. J Women’s Health Gend.Based.Med. 11[7], 601-615. 2002.
  41. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 45[6], 525-538. 1998.
  42. Ravic M, Salas-Herrera I, Johnston A, Turner P, Foley K, Rosenow D. Influence of lornoxicam a new non-steroidal antiinflammatory drug on lithium pharmacokinetics. Human Psychopharmacology 8, 289-292. 1993.
  43. Ravic M, Salas-Herrera I, Johnston A, Turner P, Foley K, Rosenow DE. A pharmacokinetic interaction between cimetidine or ranitidine and lornoxicam. Postgrad. Med. J. 69[817], 865-866. 1993.
  44. Nahler G. An open study to determine the effect of renal insufficiency on the pharmacokinetics of Lornoxicam and to assess the tolerability of the drug in patients with renal insufficiency (CT 74). Data on File, editor. 19-8-1993. Nycomed.
  45. Radhofer-Welte S. Pharmacokinetics and tolerability of Lornoxicam film-coated tablets on patients suffering from mild, moderate and severe renal impairment. Data on File, editor. 13-5-1993. Nycomed.
  46. Warrington SJ, et al. Chlortenoxicam and renal function of normal human volunteers. Letter to the editor. Human Toxicology 8[1], 53-54. 1989.
  47. Ehrenkrook DV, Glocker B. Evaluation of potential pharmacokinetic interaction between Aspirin and Chlortenoxicam (Lornoxicam) in healthy men (CT 47). Data on File, editor. 7-6-1993. Nycomed.
  48. Ravic M, Johnston A, Turner P, Foley K, Rosenow D. Letters to the editor - Doses bismuth chelate influence lornoxicam absorption? Human & Experimental Toxicology 11, 59-61. 1992.
  49. Welte S, Ferber HP, Binder D. A single dose pharmacokinetic and tolerance study of a new non steroidal anti-inflammation drug CLTX. III World Conference on Clinical Pharmacology & Therapeutics, Stockholm , 55, Abstract 89. 1986.
  50. Walden RJ, Owens CWI, Graham BR, Snape A, Nutt J, Prichard BNC. НПВПs and the control of hypertension: a pilot study. British Journal of Clinical Pharmacology 33[2], 241P. 1992.
  51. Hitoglou-Makedou A, Lawson M, Turner P, Ferber HP. Comparison of chlortenoxicam and indomethacin on frusemide-induced diuresis. Postgraduate Medical Journal 65, 821-823. 1989.
  52. Ravic M, Johnston A, Turner P. Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs. Postgraduate Medical Journal 66 [Suppl. 4], S30-S34. 1990.
  53. N.N. Study of Possible Pharmacokinetic Interaction between Chlortenoxicam and Methotrexate in Patients with Chronic Arthritis. Data on File, editor. 8-7-1993. Nycomed.
  54. Masche UP, Rentsch KM, von Felten A, Meier PJ, Fattinger KE. Opposite effects of lornoxicam co-administration on phenprocoumon pharmacokinetics and pharmacodynamics. Eur. J. Clin. Pharmacol. 54[11], 857-864. 1999.
  55. Masche UP, Rentsch KM, von Felten A, Meier PJ, Fattinger KE. No clinically relevant effect of lornoxicam intake on acenocoumarol pharmacokinetics and pharmacodynamics. Eur. J. Clin. Pharmacol. 54[11], 865-868. 1999.
  56. Ravic M, Johnston A, Turner P, Ferber HP. A study of the interaction between lornoxicam and warfarin in healthy volunteers. Human & Experimental Toxicology 9, 413-414. 1990.

Далее: Клиническая эффективность в регулировании боли

1 марта 2008 г.

МЕДИ РУ в: МЕДИ РУ на YouTube МЕДИ РУ в Twitter МЕДИ РУ на FaceBook МЕДИ РУ вКонтакте Рейтинг@Mail.ru Яндекс.Метрика